Prescribing overview
Targeted antineoplastic treatment for a defined group of recurrent canine mast cell tumors.
Tumor response and toxicity guide continued treatment. Serious gastrointestinal injury and vascular complications can occur.
Key prescribing checks
- Read the product-specific safety section and monitoring plan before selecting a treatment.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
US veterinary labelPatnaik grade II or III recurrent cutaneous mast cell tumors, with or without regional lymph node involvement
Other cancers or species are outside this reviewed label scope.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Inhibits selected receptor kinases, including KIT, VEGFR2 and PDGFR, affecting tumor growth and angiogenesis.
Absorption, distribution, metabolism and elimination
Extensive tissue distribution, high protein binding and hepatic metabolism; exposure varies among dogs.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Palladia
US veterinary label; Oral tablets.
Contraindications · when not to use
- Do not use in breeding, pregnant or lactating dogs.
Precautions & monitoring
- Evaluate possible systemic mast cell disease. Toxicity can require treatment interruption. Plan surgery timing with the oncologist because of vascular risk.
Selected product scope; does not establish suitability for other species, routes or formulations.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Diarrhea, appetite loss, vomiting, lethargy, lameness, weight loss, neutropenia and GI bleeding are reported.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this reference. The veterinarian must select the exact product-label protocol for the patient, indication and route; this entry does not enable an automatic dose.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
Palladia
US veterinary label; Oral tablets.
- NSAIDs increase concern for GI ulceration/perforation; strong CYP3A4 inhibitors may increase exposure.
Monitoring
Track CBC, kidney values, albumin, body weight and GI signs; follow the label’s early frequent and ongoing reassessment schedule.
Client counseling
Do not split tablets. Wear gloves for damaged tablets and contaminated waste; follow the written stop-and-call plan.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Keep in the original child-resistant container at labeled room temperature; use oncology handling precautions.
Brands, formulations & ingredient identity
Active ingredients
Toceranib phosphate
Palladia contains toceranib phosphate; oncology use requires individualized reassessment.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Palladia
- Formulation
- Oral tablets
- Label / product scope
- Dogs
Other cancers or species are outside this reviewed label scope.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →